Soligenix, Inc. (SNGX) is a late-stage biopharmaceutical company committed to designing and developing transformational products to treat rare diseases where there is an unmet medical need. With a highly diverse portfolio of candidates, Soligenix is mainly focused on complex biotherapeutic products for life-threatening conditions like cutaneous t-cell lymphoma, oral mucositis, cancer, GI disorders, and various types of vaccines.
Based in Princeton, New Jersey, USA, Soligenix works with an unwavering commitment to accelerating the development of new treatments for unmet medical needs. To ensure maximum efficacy and safety in their products, they employ a cutting-edge technology and science-based approach.
Soligenix operates through two business segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment focuses on the development of a novel photodynamic therapy using synthetic hypericin, a compound activated by safe, visible light for the treatment of cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin's lymphoma. This segment also focuses on the development of other rare disease drug candidates. The Vaccines/BioDefense segment includes researches on vaccines and therapeutics for military and civilian applications, primarily addressing emerging and antibiotic-resistant infectious diseases.
The company's leading BioTherapeutics product candidates are based on first-in-class photodynamic therapy utilizing safe visible light activation. This technology with synthetic hypericin has demonstrated compelling response rates in Phase 2 clinical trials when activated with safe visible light at the time of treatment.
The Vaccines/BioDefense business segment is very significant due to the increasing threats from bio-terrorism and emerging infectious diseases. This division is highly adept at developing medical countermeasures needed to protect against these threat agents.
Despite being relatively small in size, Soligenix's impact and potential in the biotech sphere are considerable. Its approach of focusing on rare diseases that lack sufficient treatment methods reflects an important commitment to addressing the unmet medical needs of patients globally. Thus, Soligenix, Inc. (SNGX) is dedicated to bringing new hope to patients by developing promising new therapies for diseases that do not yet have effective treatments.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
At its Annual Meeting on September 17, 2026, Soligenix shareholders approved several governance and capital structure changes, including the election of directors, a potential reverse stock split, an increase in authorized common shares, and advisory votes on executive compensation. The company also expanded its at-the-market equity program to raise an additional $2.5 million, continuing its reliance on ATM offerings. Despite these corporate developments, TipRanks’ AI Analyst, Spark, rates SNGX as "Neutral" due to weak financial performance, unfavorable technicals, and valuation constraints.
Soligenix, Inc. (NASDAQ: SNGX) is applying for funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of a vaccine against the Bundibugyo virus, in collaboration with Dr. Axel Lehrer. The application will leverage previous work on bivalent and trivalent thermostable vaccines for filoviruses using Soligenix's ThermoVax® platform. This platform offers the advantage of extended stability, crucial for vaccine distribution in regions lacking cold-chain infrastructure.
Soligenix has ended the development of its topical cutaneous T-cell lymphoma (CTCL) therapy, HyBryte, after the drug failed to meet its primary goals in a Phase III trial. The company will now focus on its pipeline candidate, dusquetide, for Behçet's disease and developing commercial opportunities for its ThermoVax platform for vaccines. This decision follows an interim analysis of the FLASH2 trial which indicated the treatment was unlikely to succeed.
Alliance Global Partners analyst James Molloy maintained a Buy rating on Soligenix (SNGX) with a price target of $1.50. Despite Molloy's historical average return, the analyst consensus on Soligenix is a Moderate Buy with an average price target of $1.50. The company recently reported a quarterly GAAP net loss of $2.82 million, an improvement from the previous year.
Soligenix, Inc. reported a Q2 2026 loss per share of $0.12 and a net loss of $2.0M, representing an 85.4% improvement from the previous year. This progress in narrowing its operating deficit, coupled with positive analyst outlooks, reflects growing confidence in the biopharmaceutical company's pipeline for rare disease treatments. The company focuses on developing therapies for underserved patient populations and operates in a niche segment with high potential returns upon successful commercialization.